Marinus Pharmaceuticals Inc (NASDAQ:MRNS) was a relative outperformer during the trading session. The stock rallied by close to 1% on relatively high volumes. The stock has been trending higher ever since it formed a strong support near the $5.02 level. The stock currently trades below all daily moving averages. The indicator for relative strength has given a fresh buy signal indicative of buying interest at current levels. The MACD oscillator has given a buy signal, which is considered bullish as it indicates a shift towards the buy side. Trades see the stock heading to levels of $8.15 in the near term.
The American Epilepsy Society recently selected two abstracts of Marinus Pharmaceuticals, Inc.’s CNS-selective GABAA modulator for the poster at its 69th Annual Meeting. The company announced that these two abstracts on the poster depict Marinus’s ganaxolone. The Annual Meeting of American Epilepsy Society is scheduled for December 4-8, 2015. This meeting will take place at Pennsylvania Convention Center in Philadelphia.
About the posters
The two posters have different titles. The first title depicts the analysis of additional responder in the phase 2 study of ganaxolone. It is meant for the patients suffering from partial onset seizures. This title is available at Poster Session #: 2.260 and is presented by the author Albena Patroneva, M.D.
In the second title, the Marinus Pharmaceuticals Inc (NASDAQ:MRNS) briefly highlights its ganaxolone intravenous formulation development. This is directed towards acute care patients. This development of the company is assisted by non-clinical toxicity studies, which were experimented on rabbits and rats. This title can be found at Poster Session #: 2.238. The author of this poster is Julia Tsai, Ph.D.
In the annual meeting of the American Epilepsy Society, Marinus Pharmaceuticals Inc will also host its scientific exhibition. There will be a depiction of many more ganaxolone –based scientific posters. One of these posters will present the latest development of the company, i.e., intravenous (IV) formulation. The pre-clinical data over this subject can be seen at the company’s exhibit.
Benefit of poster approval to the company
The 69th American Epilepsy Society’s annual meeting is a podium, which will offer several prospects to the Marinus Pharmaceuticals Inc. Also, it will showcase its latest developments and clinical data in the exhibition, which will fetch benefits for the company’s stakeholders. This will be a direct advantage to the company that shall be in a positive position at the 69th American Epilepsy Society’s annual meeting.